Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses ProSense was the.
Todd Kehrli: Thank you, Operator, and welcome to IceCure Medical s conference call to review the financial results for the 12 months ended December 31, 2022, and to provide an update on recent operational.
Rising Utilization of ProSense in the U.S. Market Generates Year-over-Year Consumable Revenue Growth Physician Adoption Continues to Grow Ahead of the FDA s.
IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023 - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the.